- Home
- DMAC vs AMBI Comparison
DMAC vs AMBI Comparison
Compare DMAC & AMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- AMBI
- Stock Information
- Founded
- DMAC 2000
- AMBI 1995
- Country
- DMAC United States
- AMBI Brazil
- Employees
- DMAC N/A
- AMBI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- AMBI Environmental Services
- Sector
- DMAC Health Care
- AMBI Industrials
- Exchange
- DMAC Nasdaq
- AMBI Nasdaq
- Market Cap
- DMAC 310.1M
- AMBI 265.0M
- IPO Year
- DMAC N/A
- AMBI N/A
- Fundamental
- Price
- DMAC $5.98
- AMBI $4.93
- Analyst Decision
- DMAC Strong Buy
- AMBI
- Analyst Count
- DMAC 3
- AMBI 0
- Target Price
- DMAC $12.33
- AMBI N/A
- AVG Volume (30 Days)
- DMAC 314.0K
- AMBI 8.5K
- Earning Date
- DMAC 08-12-2025
- AMBI 08-12-2014
- Dividend Yield
- DMAC N/A
- AMBI N/A
- EPS Growth
- DMAC N/A
- AMBI N/A
- EPS
- DMAC N/A
- AMBI N/A
- Revenue
- DMAC N/A
- AMBI $525,221,427.00
- Revenue This Year
- DMAC N/A
- AMBI N/A
- Revenue Next Year
- DMAC N/A
- AMBI N/A
- P/E Ratio
- DMAC N/A
- AMBI N/A
- Revenue Growth
- DMAC N/A
- AMBI 25.42
- 52 Week Low
- DMAC $3.19
- AMBI $3.70
- 52 Week High
- DMAC $6.82
- AMBI $8.20
- Technical
- Relative Strength Index (RSI)
- DMAC 65.09
- AMBI 52.97
- Support Level
- DMAC $5.90
- AMBI $4.77
- Resistance Level
- DMAC $6.18
- AMBI $5.09
- Average True Range (ATR)
- DMAC 0.39
- AMBI 0.29
- MACD
- DMAC 0.02
- AMBI 0.01
- Stochastic Oscillator
- DMAC 79.10
- AMBI 50.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About AMBI Ambipar Emergency Response
Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.